Oncosoft specializes in developing software solutions aimed at enhancing anti-cancer treatment. The company offers an Oncology Information Management Solution (OIMS) and employs artificial intelligence to support radiologists in cancer detection. Their applications utilize machine learning to automate various tasks in radiation therapy, including treatment site detection and organ contour generation. By streamlining workflows for radiation oncologists, Oncosoft's technologies enable healthcare professionals to allocate more time to patient care and improve the overall efficiency of radiation therapy.
Bazbiomedic
Series B in 2024
Bazbiomedic primarily focuses on offering an automatic repeat injection needle-less drug delivery device for the skin and beauty device.
LabInCube
Series A in 2024
LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials.
AITRICS develops advanced clinical solutions powered by machine learning and evidence-based analysis. Its platform transforms reactive disease care into predictive, preventive, personalized, and participatory care, enabling clinicians to enhance treatment and expand knowledge.
Bertis
Venture Round in 2024
Founded in 2014, Bertis is a South Korean company specializing in proteomics-based molecular diagnostics. It develops and commercializes cancer-related biomarkers for early detection of the disease, with its flagship product being Mastocheck, a screening method for stage 1 breast cancer.
Novorex is a biotechnology company focused on the development of small-molecule drugs aimed at treating oncology and neurological diseases. The company employs advanced technologies, including artificial intelligence, to enhance the efficiency of drug development. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to create innovative therapeutic solutions for patients with cancer and central nervous system disorders. Through its research and development efforts, Novorex seeks to provide advanced treatment options that meet the needs of patients facing serious health challenges.
Tentech
Venture Round in 2023
Tentech is a global maker of aesthetic equipment specializing in dermatology laser devices that lift the skin, improve elasticity, and reduce wrinkles, providing cosmetic laser solutions for skin care.
Medinno is a South Korean biotechnology company based in Suwon that focuses on the research and development of neural stem cell–based therapies derived from adult brain tissue for degenerative neurological diseases. It develops cell therapeutics for brain disorders, with applications including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, severe intraventricular hemorrhages, stroke, and Alzheimer's disease.
INTAKE foods
Series B in 2023
INTAKE foods specializes in food content development and branding. It focuses on innovating leading food brands through brand development and publishing engaging food-related activities.
PinotBio
Venture Round in 2023
PinotBio, founded in 2017, is a biotechnology company based in Suwon, South Korea. It specializes in the research and development of new small molecule drugs for ophthalmology and oncology fields.
Onconic Therapeutics
Series B in 2022
Onconic Therapeutics focuses on researching and developing innovative treatments for gastrointestinal diseases and cancers, addressing significant unmet medical needs.
Oncosoft
Venture Round in 2022
Oncosoft specializes in developing software solutions aimed at enhancing anti-cancer treatment. The company offers an Oncology Information Management Solution (OIMS) and employs artificial intelligence to support radiologists in cancer detection. Their applications utilize machine learning to automate various tasks in radiation therapy, including treatment site detection and organ contour generation. By streamlining workflows for radiation oncologists, Oncosoft's technologies enable healthcare professionals to allocate more time to patient care and improve the overall efficiency of radiation therapy.
New Base provides a systematic disaster training solution.
HEXAR Humancare
Series A in 2022
HEXAR Humancare develops and produces wearable robots.
IVIM Technology
Series C in 2022
IVIM Technology, founded in 2017 and based in Daejeon, South Korea, specializes in developing and manufacturing advanced medical devices, particularly the IntraVital Microscopy platform. The company provides services such as live cell intravital imaging, repetitive intravital imaging, drug efficacy monitoring, delivery monitoring, and whole tissue 3D imaging. IVIM Technology's innovations focus on exploring cellular interactions within living organisms to understand complex human diseases better. Their technology is instrumental in analyzing the in vivo efficacy of new biopharmaceuticals, including immunological, cell, gene, and antibody therapeutic agents, at the cellular level.
Immuneoncia Therapeutics
Secondary Market in 2022
ImmuneOncia Therapeutics Inc. is a biopharmaceutical company focused on developing anti-cancer therapies, specifically in the field of immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company is headquartered in Yongin-Si, South Korea. ImmuneOncia is dedicated to creating safe and effective immunotherapies for cancer patients worldwide, leveraging the expertise of its parent companies in drug development and antibody engineering. The company’s lead product, IMC-001, is a monoclonal antibody currently undergoing Phase 1 clinical trials, with a portfolio that includes various immune checkpoint antibodies aimed at treating multiple cancer types.
Colavo Salon is a rapidly growing customer relationship management (CRM) software company focused on the beauty industry. It offers a comprehensive platform designed to assist independent beauty professionals and salon owners in managing their businesses more efficiently. The software includes features such as online reservation management, schedule organization, sales tracking, report generation, and customer information handling. By automating back-office tasks, Colavo Salon enables its users to save time and enhance customer retention, potentially increasing it by up to 50% through intelligent booking systems and customizable reminders that follow the entire customer journey.
MitoImmune Therapeutics
Series B in 2021
MitoImmune Therapeutics is a biotechnology company focused on drug research and development aimed at treating mitochondrial dysfunction and various cellular disorders. The company specializes in creating therapies for diseases related to mitochondrial dysfunction, including necrotic and inflammatory conditions. By developing targeted treatments, MitoImmune Therapeutics aims to enhance the quality of life for patients suffering from these complex health issues.
Onegene Biotechnology
Series A in 2021
Onegene Biotechnology is a biotechnology company focused on developing innovative protein-based drugs to treat cancer, metabolic, and inflammatory diseases. The company specializes in creating highly potent tri- or multispecific protein drugs by combining various molecular types, including Fab fragments, scFv, sdAb, peptides, cytokines, agonists/antagonists, and enzymes. This approach allows for an unprecedented level of design flexibility with optimized physical properties, opening new avenues for developing complex protein drugs that are feasible to manufacture. Onegene's technology involves protein conjugation, which connects two separate proteins to produce therapeutic recombinant proteins through post-translational fusion. This method enables the production of multi-target proteins with large molecular weights, providing prolonged holistic benefits for treating complex and multifactorial diseases.
Primoris Therapeutics
Seed Round in 2021
Primoris Therapeutics is a medical research and development center.
Bertis
Venture Round in 2020
Founded in 2014, Bertis is a South Korean company specializing in proteomics-based molecular diagnostics. It develops and commercializes cancer-related biomarkers for early detection of the disease, with its flagship product being Mastocheck, a screening method for stage 1 breast cancer.
Dr. Noah Biotech
Series A in 2020
Dr. Noah Biotech is a pharmaceutical company that specializes in developing drugs for patients with rare diseases (orphan diseases). It utilizes artificial intelligence and big data analysis to efficiently identify novel drug combinations, particularly for conditions affecting fewer than 200,000 people in the United States.
CORELINESOFT
Series B in 2020
CORELINESOFT develops medical software products.
AITRICS develops advanced clinical solutions powered by machine learning and evidence-based analysis. Its platform transforms reactive disease care into predictive, preventive, personalized, and participatory care, enabling clinicians to enhance treatment and expand knowledge.
MitoImmune Therapeutics
Series A in 2019
MitoImmune Therapeutics is a biotechnology company focused on drug research and development aimed at treating mitochondrial dysfunction and various cellular disorders. The company specializes in creating therapies for diseases related to mitochondrial dysfunction, including necrotic and inflammatory conditions. By developing targeted treatments, MitoImmune Therapeutics aims to enhance the quality of life for patients suffering from these complex health issues.
JLK, Inc. is a South Korean company specializing in artificial intelligence-driven medical and security solutions. It develops advanced AI platforms that support diagnosis and treatment by providing real-time, on-site services integrated with hospital systems. JLK focuses on a range of medical conditions, offering solutions for brain diseases such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease, as well as lung diseases, coronary artery disease, and prostate cancer. The company also emphasizes digital pathology and data analysis in its offerings. Formerly known as JLK INSPECTION Co., Ltd., JLK, Inc. is headquartered in Cheongju, South Korea.